Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin farnesil

Immunopharmacology

Volumn 44, Issue 3, 1999, Pages 245-254

  Hirohata, Shunsei ^a   Yanagida, Tamiko ^a   Kawai, Mami ^a   Kikuchi, Hirotoshi ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B cells; Farnesol; Immunoregulation; NSAID

Indexed keywords

BIS(4 NITROPHENYL) PHOSPHATE; CARBOXYLESTERASE; CD71 ANTIGEN; CD98 ANTIGEN; FARNESOL; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INDOMETACIN; INDOMETACIN FARNESIL; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; B-LYMPHOCYTES; CELLS, CULTURED; FARNESOL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INDOMETHACIN; INTERLEUKIN-18; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0032793358     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00084-3     Document Type: Article

References (30)

1. Aylward M., Maddock J., Wheeldon R., Parker R.J. A study of the influence of antirheumatic drug regimens on serum acute-phase proteins, plasma tryptophan, and erythrocyte in rheumatoid arthritis. Rheumatol. Rehabil. 14:1975;101-114.
2. Casey P.J. Protein lipidation in cell signaling. Science. 268:1995;221-225.
3. Ceuppens J.L., Rodriguez M.A., Goodwin J.S. Non-steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet. I:1982;528-530.
4. Ceuppens J.L., Robaeys G., Verdickt W., Vertessen S., Deckmyn H., Dequeker J. Immunomodulatory effects of treatment with naproxen in patients with rheumatic disease. Arthritis Rheum. 29:1986;305-311.
5. Clements, P.J., Paulus, H.E., 1993. Nonsteroidal anti-inflammatory drugs. In: Kelly, W.N., Harris, E.D., Jr., Ruddy, S., Sledge, C.B. (Eds.), Textbook of Rheumatology, 4th edn. Saunders, Philadelphia, pp. 700-730.
6. The Cooperating Clinics Committee of the American Rheumatism Association A three-month trial of indomethacin in rheumatoid arthritis, with special reference to analysis and inference. Clin. Pharmacol. Ther. 8:1967;11-37.
7. Cox A.D., Hisaka M.M., Buss J.E., Der C.J. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol. Cell. Biol. 12:1992;2606-2615.
8. Cush J.J., Jasin H.E., Johnson R., Lipsky P.E. Relationship between clinical efficacy and laboratory correlates on inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 33:1990;623-633.
9. Dixon J.S., Bird H.A., Sitton N.G., Pickup M.E., Wright V. C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. Scand. J. Rheumatol. 13:1984;39-44.
10. Favero A.D. Side-effects of drug; anti-inflammatory analgesics and drug used in rheumatism and gout. Excepta Medica. 10:1981;88-117.
11. Geppert T.D., Lipsky P.E. Accessory cell-independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J. Immunol. 138:1987;1660-1666.
12. Harris E.D. Jr. Pathogenesis of rheumatoid arthritis and the development of rational drug therapy. J. Rheumatol. 9:1982;3-9.
13. Hart F.D., Huskisson E.C. Nonsteroidal anti-inflammatory drugs: current status and rational therapeutic use. Drugs. 24:1984;232-255.
14. Hirohata S., Yamada A., Inoue T. A sensitive and simple method for determination of IgM in cerebrospinal fluid by a solid-phase enzyme immunoassay: comparison of two different methods. J. Neurol. Sci. 67:1985;115-118.
15. Hirohata S., Oka H. Modulation of T cell production of interferon-γ by human monocytes: effect of engagement of CD14 on monocytes. Cell. Immunol. 151:1993;270-282.
16. Hirohata S., Konuma K., Inoue T., Ito K. Interaction of indometacin farnesil, a new nonsteroidal anti-inflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis. Jpn. J. Clin. Immunol. 19:1996;136-144.
17. Hirohata S. Inhibition of human B cell activation by gold compounds. Clin. Immunol. Immunopathol. 81:1996;175-181.
18. Hirohata S., Nakanishi K., Yanagida T., Kawai M., Kikuchi H., Isshi K. Synergistic inhibition of human B cell activation by gold sodium thiomalate and auranofin. Clin. Immunol. 41:1999;226-233.
19. Kobayashi S., Hashida R., Shirota H., Yoshimatsu K., Harada K., Abe S., Yamatsu I., Mizushima Y., Nagai Y. Effect of E-0710, a farnesyl ester of indomethacin, on rat synovial cell prostaglandin production in culture. Drug Exp. Clin. Res. 10:1984;845-851.
20. Levy J. Enhancement of deficient T cell function in rheumatoid arthritis by tolmetin sodium. J. Clin. Pharmacol. 23:1983;324-328.
21. McConkey B., Crockson R.A., Crockson A.P., Wilkinson A.R. The effects of some anti-inflammatory drugs on the acute phase proteins in rheumatoid arthritis. Q. J. Med. 42:1973;785-791.
22. Mishima M., Kobayashi S., Hashida R., Yuzuriha T., Sato S., Satoh T. Enzymatic hydrolysis of indometacin farnesil, a prodrug of indomethacin, by carboxylesterase in cultured synovial cells. Res. Commun. Chem. Pathol. Pharmacol. 72:1991;183-190.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
24. Shiokawa Y., Miyamoto T., Hirose S., Sugawara S.et al. Clinical evaluation of E-0710 in rheumatoid arthritis: a multicenter double-blind trial with indomethacin. Shinryo to Shinyaku. 26:1989;565-596. in Japanese.
25. Spiers E.M., Tavendale A., MacConnachie A., Swanson B.J. The effect of non-steroidal anti-inflammatory drugs on phytohemagglutinin stimulated lymphocytes: relevance to possible therapeutic immunosuppression by fenclofenac. Int. J. Immunopharmacol. 10:1988;261-269.
26. Thiele D.L., Kurosaka M., Lipsky P.E. Phenotype of the accessory cell necessary for mitogen- stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotrophic agent, L-leucine methyl ester. J. Immunol. 131:1983;2282-2290.
27. Thoen J., Helgetveit K., Førre Ø., Haile T., Kass E. Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells, and rheumatoid factor production in rheumatoid arthritis. Scand. J. Rheumatol. 17:1988;91-102.
28. Verbreeck R.K., Blackburn J.L., Loewen G.R. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics. 8:1983;297-331.
29. Wright V., Amos R. Do drugs change the course of rheumatoid arthritis? Br. Med. J. 280:1980;964-966.
30. Yesair D.W., Callahan M., Remington L., Kensler C.J. Role of the enterohepatic cycle of indomethacin on its metabolism. Distribution in tissues and its excretion by rats, dog and monkeys. Biochemical Pharmacology. 19:1970;1579-1590.